Curcumin Inhibits LPS-induced Inflammation in Rat Vascular Smooth Muscle Cells in Vitro Via ROS-relative TLR4-MAPK/NF-κB Pathways
Overview
Affiliations
Aim: To investigate whether curcumin (Cur) suppressed lipopolysaccharide (LPS)-induced inflammation in vascular smooth muscle cells (VSMCs) of rats, and to determine its molecular mechanisms.
Methods: Primary rat VSMCs were treated with LPS (1 μg/L) and Cur (5, 10, or 30 μmol/L) for 24 h. The levels of MCP-1, TNF-α, and iNOS were measured using ELISA and real-time RT-PCR. NO level was analyzed with the Griess reaction. Western-blotting was used to detect the activation of TLR4, MAPKs, IκBα, NF-κB p65, and the p47(phox) subunit of NADPH oxidase in the cells.
Results: Treatment of VSMCs with LPS dramatically increased expression of inflammatory cytokines MCP-1 and TNF-α, expression of TLR4 and iNOS, and NO production. LPS also significantly increased phosphorylation of IκBα, nuclear translocation of NF-κB (p65) and phosphorylation of MAPKs in VSMCs. Furthermore, LPS significantly increased production of intracellular ROS, and decreased expression of p47(phox) subunit of NADPH oxidase. Pretreatment with Cur concentration-dependently attenuated all the aberrant changes in LPS-treated VSMCs. The LPS-induced overexpression of MCP-1 and TNF-α, and NO production were attenuated by pretreatment with the ERK inhibitor PD98059, the p38 MAPK inhibitor SB203580, the NF-κB inhibitor PDTC or anti-TLR4 antibody, but not with the JNK inhibitor SP600125.
Conclusion: Cur suppresses LPS-induced overexpression of inflammatory mediators in VSMCs in vitro via inhibiting the TLR4-MAPK/NF-κB pathways, partly due to block of NADPH-mediated intracellular ROS production.
Investigating antibacterial and anti-inflammatory properties of synthetic curcuminoids.
Vesela K, Kejik Z, Abramenko N, Kaplanek R, Jakubek M, Petrlova J Front Med (Lausanne). 2024; 11:1478122.
PMID: 39534226 PMC: 11554473. DOI: 10.3389/fmed.2024.1478122.
Benefits of Some Phytochemical Compounds in Experimental Sepsis Models: A Therapeutic Perspective.
Ozdemir B, Bayram P, Karamese S Eurasian J Med. 2024; 55(1):157-164.
PMID: 39128074 PMC: 11075035. DOI: 10.5152/eurasianjmed.2023.23382.
The emerging role of oxidative stress in inflammatory bowel disease.
Muro P, Zhang L, Li S, Zhao Z, Jin T, Mao F Front Endocrinol (Lausanne). 2024; 15:1390351.
PMID: 39076514 PMC: 11284038. DOI: 10.3389/fendo.2024.1390351.
Zhu J, He L Microorganisms. 2024; 12(4).
PMID: 38674587 PMC: 11052165. DOI: 10.3390/microorganisms12040642.
Di Paola A, Marrapodi M, Pota E, Colucci Cante R, Rana D, Giliberti G Cancers (Basel). 2024; 16(4).
PMID: 38398105 PMC: 10886672. DOI: 10.3390/cancers16040714.